Market Research Report
Nanoparticles in Biotechnology, Drug Development and Drug Delivery
|Published by||BCC Research||Product code||251476|
|Published||Content info||192 Pages
|Nanoparticles in Biotechnology, Drug Development and Drug Delivery|
|Published: August 29, 2014||Content info: 192 Pages||
The global market for nanoparticles in biotechnology and pharmaceuticals reached nearly $25.0 billion in 2013. This market is expected to reach $29.6 billion in 2014 and $79.8 billion in 2019, with a compound annual growth rate (CAGR) of 22.0% for the period of 2014 to 2019.
Current and projected product forecasts during the forecast period of 2014 through 2019 are discussed. New product launches will be discussed. Revenue figures for 2013 are actual figures except where actual results have not been reported due to the timing of this report's release.
The report includes analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.
Market figures are based on revenues at the manufacturer level and are projected at 2013-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.
Included in this report are forecasts by product, product category and by company from 2012 through 2019. The study is arranged to offer an overview of existing nanoparticle technology and of drug markets; it is accompanied by nanoproduct, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country.
Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis unless specifically noted.
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early and mid-stage drug development.